1) To determine if 5 doses of Epo (Erythropoietin) 1000 U/kg (birth weight) intravenous (IV) reduces the rate of death or neurodevelopmental impairment (mild, moderate, or severe) at 24 months of age.
2) To assess safety of Epo.
3) To determine whether Epo decreases the severity of HIE-induced brain injury as evidenced by early MRI and plasma biomarkers of brain injury.
We are interested in observing whether and how infants learn when interacting with a robot during a learning assessment contingency paradigm.
Our goal is early identification of deviation from healthy brain development to allow targeted early intervention and improve developmental outcomes.
The collection of the research data we hope will help better screening, diagnosing procedures and treatment of brain injury in newborns and identify a connection between MR imaging and neurodevelopmental outcomes.
This research is being done to test the safety and effectiveness of intranasal carbetocin to treat Prader Willi Syndrome.
Our purpose is to look at the long-term neurodevelopmental outcomes of preterm neonatal brain abnormalities.
Understand the experiences of patients and parents in treatment decision making for children with Neuromuscular Scoliosis (NMS).
The primary aim of this registry will be to identify genes and/or biologic and environmental factors that either cause these tumors or increase one's risk for developing them. Ultimately, research using this registry may result in improved diagnosis, more effective treatments and possibly prevention.
